BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19672286)

  • 21. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
    Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
    BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma.
    Liu YY; Yao SN; Zhao Y; Yao ZH; Ma J; Xia QX; Fu K; Yang SJ
    Leuk Lymphoma; 2010 Sep; 51(9):1692-8. PubMed ID: 20807096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement.
    Frank I; Cheville JC; Blute ML; Lohse CM; Karnes RJ; Weaver AL; Sebo TJ; Nehra A; Zincke H
    Cancer; 2004 Oct; 101(8):1803-8. PubMed ID: 15386300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
    Stewart DA; Bahlis N; Mansoor A
    Leuk Lymphoma; 2009 Aug; 50(8):1276-82. PubMed ID: 19562614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.
    Nakayama S; Matsuda M; Adachi T; Sueda S; Ohashi Y; Awaji S; Hashimoto S; Matsumura I
    Platelets; 2019; 30(5):637-645. PubMed ID: 30047815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
    Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
    J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
    Xie Y; Bulbul MA; Ji L; Inouye CM; Groshen SG; Tulpule A; O'Malley DP; Wang E; Siddiqi IN
    Am J Clin Pathol; 2014 Apr; 141(4):593-604. PubMed ID: 24619762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry.
    Maartense E; Kramer MH; le Cessie S; Kluin-Nelemans JC; Kluin PM; Snijder S; Noordijk EM
    Leuk Lymphoma; 2004 Jan; 45(1):101-7. PubMed ID: 15061204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma.
    Auw-Haedrich C; Coupland SE; Kapp A; Schmitt-Gräff A; Buchen R; Witschel H
    Br J Ophthalmol; 2001 Jan; 85(1):63-9. PubMed ID: 11133714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.
    Richardson AI; Zhang D; Woodroof J; Cui W
    Hum Pathol; 2019 Apr; 86():21-31. PubMed ID: 30496802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: an immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status.
    Moriki T; Takahashi T; Kataoka H; Hiroi M; Yamane T; Hara H
    Pathol Int; 1996 Dec; 46(12):953-61. PubMed ID: 9110347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic implication of p53 protein expression in relation to nuclear pleomorphism and the MIB-1 counts in breast cancer.
    Tsutsui S; Yasuda K; Higashi H; Tahara K; Sugita S; Eguchi H; Kayashima H; Miyazaki N; Muto Y; Era S
    Breast Cancer; 2004; 11(2):160-8. PubMed ID: 15550862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma.
    Pătraşcu AM; Rotaru I; Olar L; Pătraşcu Ş; Ghiluşi MC; NeamŢu SD; Nacea JG; Gluhovschi A
    Rom J Morphol Embryol; 2017; 58(3):837-843. PubMed ID: 29250662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.
    Coutinho R; Lobato J; Esteves S; Cabeçadas J; Gomes da Silva M
    Ann Hematol; 2019 Aug; 98(8):1937-1946. PubMed ID: 30949752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
    Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
    PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ki-67 proliferative index in non-Hodgkin's lymphoma and its clinical significance].
    Li J; Hu R; Liao AJ; Shi HY; Yan W; Liu ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):935-9. PubMed ID: 21867618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior.
    Costa MJ; Walls J; Ames P; Roth LM
    Hum Pathol; 1996 Mar; 27(3):274-81. PubMed ID: 8600043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.